> **#132**

**The Administrative New Animal Drug Application**

**Process**

**DRAFT GUIDANCE**

(This document is being distributed for comment purposes only)

This draft guidance describes the Center for Veterinary Medicine's
Administrative New Animal Drug Application process.

Comments and suggestions regarding this draft document should be sent to
the Dockets Management Branch (HFA-305), Food and Drug Administration,
5630 Fishers Lane, Room 1061, Rockville, MD 20852. Submit electronic
comments to http://www.fda.gov/dockets/ecomments. All comments should be
identified with Docket Number 02D-0449.

For questions regarding this draft guidance document, contact Gail
Schmerfeld, Center for Veterinary Medicine (HFV- 100), Food and Drug
Administration, 7500 Standish Place, Rockville, MD 20855, 301-827-1796
(e-mail: gschmer1@cvm.fda.gov)

**U.S. Department of Health and Human Services**

**Food and Drug Administration**

**Center for Veterinary Medicine (CVM)**

**November 6, 2002**

**Guidance for Industry**

**The Administrative New Animal Drug Application**

**Process**

**DRAFT GUIDANCE**

**This draft guidance represents the agency's current thinking on this
matter. It does not create or confer any rights for or on any person and
does not bind the Food and Drug Administration (FDA) or the public. An
alternative approach may be used if such approach satisfies the
requirements of the applicable statute and regulations.**

## Purpose of this Guidance

This guidance defines what an "Administrative New Animal Drug
Application (NADA)" is, the procedures that should be followed if a
sponsor elects to submit an Administrative NADA, and the intended time
frame for review of Administrative NADAs.

# II. Background

The Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 321, et
seq.) prohibits the introduction into interstate commerce of new animal
drugs that are not the subject of an approved new animal drug
application (NADA). Section 512(b) of the Act describes the information
that must be submitted to the FDA as part of an NADA.

The Center for Veterinary Medicine (CVM) encourages sponsors to submit
data for review at the most appropriate and productive times in the drug
development process rather than submitting all data at one time.
Sponsors may submit for CVM "phased review" data in support of discrete
technical sections during the investigation of the new animal drug.
Submissions containing technical information should be submitted to the
investigational new animal drug (INAD) file for "direct review" by the
Division responsible for the technical evaluation.

Phased review and direct review create greater efficiencies that
facilitate the approval of new animal drugs. This guidance defines what
an Administrative NADA is, describes the phased review process, and
discusses how sponsors should submit an Administrative NADA and the time
frame for review.

### 

### 

### III. The Administrative NADA process

**[Definition]{.underline}:** An "Administrative NADA" is a new animal
drug application that is submitted after all of the technical sections
that fulfill the requirements for the approval of the new animal drug
under 21 CFR 514.1 have been reviewed by CVM and CVM has issued a
technical section complete letter for each of those technical sections.

**[The Phased Review Process]{.underline}**

A sponsor may submit data or information in support of a technical
section, or may submit a complete technical section, of the NADA for
review during the investigation of the new animal drug, i.e., for phased
review. The same requirements under 21 CFR 514.1 apply to all NADAs
whether for phased review or not. Phasing of NADA submissions is a
voluntary program.[^1] The option to phase the review of data
submissions applies to all original NADAs and to supplemental NADAs and
can be exercised up to the point at which the sponsor submits an NADA or
supplemental NADA. Applicants making submissions relating to abbreviated
NADAs and supplements should contact the Generic Animal Drug Team to
discuss whether phased review is appropriate for their particular
generic new animal drug.

If a sponsor exercises the option to use the phased review process:

> A. Submissions relating to technical sections should be submitted
> during the investigation of the new animal drug and filed in an
> Investigational New Animal Drug (INAD) file established by CVM for the
> new animal drug.
>
> B. Each submission should contain information and data relating to
> only one technical section and should be under a separate cover.
> Sponsors are encouraged to contact the reviewing Division regarding
> what information and data should be submitted together.
>
> C. Each submission relating to a different technical section should be
> bound separately and should include a cover letter**,** a table of
> contents, a summary, and other information pertinent to the review of
> the particular section. The envelope in which a submission is mailed
> should be addressed to the Document Control Unit, HFV-199, CVM, FDA,
> 519 Standish Place, Rockville, MD 20855. The cover letter should: (1)
> at the top identify the submission as a "Phased Submission;" (2) be
> addressed to the Division or Staff Director responsible for the
> evaluation of the technical section; (3) briefly describe the purpose
> of the submission and the information contained in it, including
> reference to any pertinent previous correspondence between CVM and the
> sponsor; (4) reference or attach any pertinent documentation regarding
> previous agreements or understandings between the sponsor and CVM; (5)
> identify persons the agency may contact regarding any specifics of the
> submission; and/or (6) convey any other information the sponsor
> considers important or necessary to facilitate the review of the
> submission**.**
>
> D. There are potentially eight technical sections: Chemistry,
> Manufacturing, and Controls; Effectiveness; Target Animal Safety;
> Human Food Safety; Environmental Impact; Labeling; Freedom of
> Information (FOI) Summary; and, All Other Information. These technical
> sections are described briefly below. Additionally, the FOI Summary is
> described in greater detail in 21 CFR § 514.11(e)(2) and each of the
> other technical sections is described in greater detail in 21 CFR
> § 514.1.
>
> \(1\) The **Chemistry, Manufacturing, and Controls** section should
> contain complete information regarding the manufacture of the new
> animal drug active ingredient and the new animal drug product. It
> should include information on personnel, facilities, components and
> composition, manufacturing procedures, analytical specifications and
> methods, control procedures, stability, containers and closures, Good
> Manufacturing Practice (GMP) compliance, and many other aspects of the
> chemistry and manufacturing processes.
>
> \(2\) The **Effectiveness** section must contain full reports of all
> studies that show whether or not the new animal drug is effective for
> its intended use. 21 CFR § 514.1(b)(8)(i). This section should include
> both studies with controls and studies without controls conducted by
> or on behalf of the sponsor or available to the sponsor by right of
> reference. References and authorizations, if appropriate, to other
> applications or documents containing information regarding
> effectiveness of the new animal drug should also be included in this
> section of the application. Section 512(d)(1)(E) of the Act, 21 USC §
> 360b(d)(1)(E), provides that CVM must refuse to approve an NADA unless
> the sponsor demonstrates by substantial evidence that the drug will
> have the effect it purports or is represented to have under the
> conditions of use prescribed, recommended, or suggested in the
> proposed labeling.
>
> \(3\) The **Target Animal Safety** section must contain full reports
> of all studies that show whether or not the new animal drug is safe to
> the target species. 21 CFR § 514.1(b)(8)(i). All studies should
> include those studies conducted by or on behalf of the sponsor or
> available to the sponsor by right of reference. References and
> authorizations, if appropriate, to other applications or documents
> containing information regarding safety of the new animal drug should
> also be included in this section of the application.

(4) The **Human Food Safety** section is submitted only for applications
    for new animal drugs intended for use in species that are used for
    human food (food-producing animals). This section must, by
    regulation, 21 CFR § 514.1(b)(7), include a description of
    practicable methods for determining the quantity, if any, of the new
    animal drug in or on food, and any substance formed in or on food
    because of its use, and the proposed tolerance or withdrawal period
    or other use restrictions to ensure that the proposed use of the
    drug will be safe. This section should also contain any data
    relating to residue toxicology (including the impact of residues on
    human intestinal microflora), residue chemistry, and, if the new
    animal drug has anti-infective properties, microbial food safety.
    When it becomes final, see CVM draft guidance #52, "Microbiological
    Testing of Antimicrobial Drug Residues in Food."

> \(5\) The **Environmental Impact** section must, by regulation, 21 CFR
> § 514.1(b)(14), contain either an environmental assessment (EA) under
> 21 CFR § 25.40, or a request for categorical exclusion under 21 CFR
> § 25.30 or 25.33. Under 21 CFR § 25.15(a), a claim of categorical
> exclusion must include a statement of compliance with the categorical
> exclusion criteria and must state that to the sponsor's knowledge, no
> extraordinary circumstances exist. "Environmental Impact
> Considerations" and directions for preparing an EA can be found in 21
> CFR Part 25.
>
> \(6\) The **Labeling** section should include facsimile copies of
> container labels, package inserts and any other labeling that will be
> used with the products. For medicated feeds, copies of representative
> labeling for the Type B and Type C medicated feeds, referred to as
> "Blue Bird" labeling, should also be included. Facsimile labeling is
> nearly final labeling that adequately reproduces the package size
> (actual or to scale); graphics; pictures; type size, font, and color
> of text; and, the substance of the text to demonstrate to the
> reviewing Division that the final printed labeling will be in
> compliance with applicable regulations. Labeling should address any
> user safety concerns identified during the review process. See 21
> U.S.C. § 502(f)(2).
>
> \(7\) The completed **FOI Summary** should include the specific
> language relevant to a technical section that was agreed upon during
> the review of the individual technical section (e.g., the tolerance
> and withdrawal time for a new animal drug intended for use in
> food-producing animals) and should be accepted by the Division
> responsible for the evaluation of the target animal safety technical
> section. For further information on FOI summaries, see 21 CFR
> 514.11(e)(2)(ii).
>
> \(8\) The **All Other Information** section must include all other
> information, not included in any of the other technical sections, that
> is pertinent to an evaluation of the safety or effectiveness of the
> new animal drug for which approval is sought. 21 CFR
> § 514.1(b)(8)(iv). All other information includes, but is not limited
> to, any information derived from other marketing (domestic or foreign)
> and favorable and unfavorable reports in the scientific literature.

E. Submissions relating to target animal safety, effectiveness, requests
for categorical exclusions, labeling, the FOI summary, and all other
information should be submitted to the appropriate Division (the
Division of Therapeutic Drugs for Non-Food Animals, the Division of
Production Drugs, or the Division of Therapeutic Drugs for Food Animals)
as determined by the intended uses for the new animal drug. Submissions
relating to Chemistry, Manufacturing, and Controls should be submitted
to the Division of Manufacturing Technologies. Environmental assessments
and Environmental Impact Statements should be submitted to the
Scientific Support Staff in the Office of the Director, ONADE. A
submission relating to Human Food Safety (Residue Toxicology, Residue
Chemistry, and Microbiology) should be submitted to the Division of
Human Food Safety. If a submission is not sent to the appropriate review
Division or Staff, processing of the submission may be delayed. Relevant
draft labeling, FOI text, and all other information should be submitted
with and reviewed concurrently with each technical section. This
facilitates the review of the labeling and FOI Summary technical
sections.

> Submissions to CVM are logged in by the Document Control Unit. Thus,
> the envelope in which a submission is mailed, or the electronic
> submission, should be addressed to the Document Control Unit, HFV-199.
> The cover letter should be directed to the Director of the Division or
> Staff responsible for the review of the submission.
>
> F. The reviewing Division will notify the sponsor in writing of its
> conclusions on acceptance or non-acceptance of the data submitted
> relevant to a technical section. If the reviewing Division finds the
> data for the technical section to be complete, it will issue a
> technical section complete letter. A final decision on the approval of
> an application will be made when the Administrative NADA is submitted
> and CVM evaluates whether all the data for all technical sections
> viewed as a whole support approval.
>
> G. Any person intending to file an NADA or a request for an
> investigational exemption under section 512(j) of the Act is
> encouraged to request one or more conferences prior to such submission
> to reach an agreement acceptable to CVM, establishing the submissions
> or investigations necessary to meet the requirements of 21 CFR 514.1.
>
> H. The synchronizing of major technical sections remains the
> responsibility of the drug sponsor. There are obvious and varying
> degrees of cross relationships among major technical sections. For
> example, concerns about target animal safety may place boundaries on
> the dose(s) evaluated in drug effectiveness studies.
>
> I. Prior to submission of the NADA, the sponsor is responsible for
> ensuring all technical sections are compatible and support the
> approval of the same drug product.

### IV. Submitting an Administrative NADA

When a sponsor has received technical section complete letters for each
of the technical sections submitted to support approval of a new animal
drug, the sponsor may file an Administrative NADA. The Administrative
NADA should include a cover letter, signed FDA Form 356V, a table of
contents, summary, a copy of each technical section complete letter,
complete facsimile labeling, and the FOI summary. The cover letter
should be addressed to the Division Director responsible for the
evaluation of the target animal safety technical section of the
application and should identify at the top of the letter that the
submission is an "Administrative NADA."

### V. Time frame for Review

Section 512(c)(1) of the Act requires FDA to approve or not approve an
NADA within 180 days, or within such additional period as FDA and the
sponsor may agree upon, after the filing of an application. The Act does
not specify the order or timing for submission of data in support of an
application. If the data are submitted as part of the phased review
process, CVM intends to consider the NADA submitted when it receives an
Administrative NADA because it is at this point that the agency should
have all the elements required by 21 CFR 514.1.

If an application meets the definition of an Administrative NADA, the
review should take fewer than 180 days because the review of the
individual sections of the application has already been completed.
However, CVM still conducts a review after it receives an Administrative
NADA. The Division responsible for the evaluation of target animal
safety will review the information submitted as part of an
Administrative NADA to ensure that all the information necessary to make
an approval decision has been provided, is complete, and is consistent
when all the technical sections are considered together.

When CVM receives an application that has been identified in the cover
letter as an "Administrative NADA", it intends to assign a 60-day review
timeframe to the application. The application will be forwarded to the
Director of the Division responsible for the evaluation of target animal
safety who will review the NADA to determine if it meets the definition
of an Administrative NADA. If the application does not meet the
definition, CVM intends to assign it the statutory 180-day timeframe in
STARS and notify the sponsor. CVM intends to evaluate all NADAs within
30 days of receipt to determine whether any of the grounds to refuse to
file the application under 21 CFR § 514.110 apply.

It is the responsibility of the sponsor to ensure that all technical
sections of an application are compatible and support the approval of a
new animal drug. In those instances in which a review of the technical
sections of the Administrative NADA together raises questions about the
safety or effectiveness of the new animal drug, CVM will refuse to
approve the application under section 512(d) of the Act. CVM encourages
the use of presubmission conferences during the drug development and
review process to minimize those occasions on which the reviewing
Division identifies problems after the Administrative NADA has been
submitted.

VI\. **Patent Term Restoration Issues**

Under U.S. patent law (35 U.S.C. § 156(a)), the term of a patent for a
new animal drug or its method of use may be extended if it meets certain
criteria, one of which is that it was subject to a regulatory review
period prior to its commercial marketing or use. While there are other
important criteria that must be met, a full discussion of the issues
relating to patent term extension is beyond the scope of this guidance.

In summary, however, the regulatory review period is divided into two
time periods. The first period (sometimes called the investigational
period) begins when the sponsor submits a request to CVM to establish an
INAD file, or when a major health or environmental effects test is
initiated, and ends when an NADA is submitted. The second period (the
approval period) begins with submission of the NADA and ends when the
application is approved. 35 U.S.C. § 156(g)(4)(B). Subject to certain
important limitations, a patent may be extended for a time roughly equal
to the second time period plus one half the first time period. 35 U.S.C.
§ 156(c)(2). Because FDA intends that the time it takes to approve an
application that qualifies as an Administrative NADA usually will be
shorter than the time it takes to approve a traditional NADA, a new
animal drug that was the subject of an Administrative NADA is likely, in
most cases, to receive a shorter patent term extension than it would
have received had it been the subject of a traditional NADA.

[^1]: In deciding whether to seek approval of a new animal drug under
    phased review or under the traditional review process by submitting
    all data together, a sponsor should consider all advantages and
    disadvantages of each mechanism for approval before submitting data
    for CVM's review. For example, a sponsor should consider whether
    seeking approval of a new animal drug under phased review will
    affect the extension of a patent term. See the discussion in section
    V. of this guidance.